REACTION BIOLOGY CORPORATION

Biotech · Acquired

Bromodomain screening assays and selective chemical probes for epigenetic drug discovery

New patent · Sep 29

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Total capital: $6.3M

Federal grants: $3.8M; 7 awards · 2015–2018; Rank in peer group#23 of 42
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $2.5M; 59 awards · Health and Human S, Interior; Rank in Biotech#124 of 4373
Granted patents: 2; 6 pending · first 2025; Rank in peer group#17 of 42

Capital timeline

Latest events

Sep 2025Federal contractInterior · Bioactive Small Molecule Development Project - Gamma 33P Atp Kinase Assay And Nanobret Kinase Assay$60K
Sep 2024Federal contractHealth and Human S · Biochemical Kinase Assays, 160 Compounds$20K
Apr 2024Federal contractHealth and Human S · Testing Of 2 Compounds Against The The Selected Kinase Panel In A Biochemical Gamma 33P- Atp Kinase Assay$21K
Feb 2024Federal contractHealth and Human S · Gamma 33P Atp Kinase Assay And Nanobret Kinase Assay Testing$101K
Dec 2023Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 [24-000909]$11K
Sep 2023Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 [23-006272]$80K
Sep 2023Federal contractHealth and Human S · Profiling 10 Btk Inhibitors Versus 20 Kinases$20K

Show 59 earlier federal awards

Sep 2023Federal contractHealth and Human S · Test Thirty-five (35) Novel Small Molecule Compounds For Inhibition Of A Set Of 3 Wild-type Kinase Enzymes.$16K
Aug 2023Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 [23-001038] Cell Profiling Of BBR-3464$27K
Sep 2022Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 [22-005623]$53K
Sep 2022Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 [22-005529]$14K
Jul 2022Federal contractHealth and Human S · Testing Of Compounds For Inhibition Of Wild-type Kinase Enzymes$110K
Feb 2022Federal contractHealth and Human S · Gamma 33P Atp Kinase Assay$38K
Jan 2022Federal contractHealth and Human S · Test 100 Compounds Against Select Kinases In A Cellular Nanobret Assay$48K
Dec 2021Federal contractHealth and Human S · Testing Of Compounds For Inhibition Of 370 Wild-type Kinase Enzymes$167K
Sep 2021Federal contractHealth and Human S · Testing Of Compounds For Inhibition Of Wild-type Kinase Enzymes$25K
Aug 2021Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 [21-005222]$15K
Jul 2021Federal contractHealth and Human S · Methyltransferase Panel Screening Using Methyltransferase Hotspot Assay For Early Translation Branch (etb) For DPI_SARS-COV-2_VARIANT Trace Project. Pop: 07/09/21 - 08/20/21$36K
Jun 2021Federal contractHealth and Human S · Kinase Screen, 377 Wild Type Kinases Versus 10 Compounds$143K
Apr 2021Federal contractHealth and Human S · Testing Of Compounds For Kinase Inhibition. Pop: April 14, 2021 To April 13, 2022. 300 Cmpds Vs. 3 Wildtype Kinases, 10 Dose IC50 Singlet Assay; And 10 Cmpds Vs. 50 Kinase Panel, 10 Dose IC50 Singlet Assay.$126K
Mar 2021Federal contractHealth and Human S · Nanobret Cellular Activity Assay, For 26 Compounds$24K
Dec 2020Federal contractHealth and Human S · Assay Development For Spr Analysis On TMPRSS2$12K
Dec 2020Federal contractHealth and Human S · The Objective Of This Order Is To Conduct A Screen To Evaluate The Interactions Between A Target (OTS964) And A Set Of 140 Cancer Cell Lines.$15K
Sep 2020Federal contractHealth and Human S · Methyltransferase And Kinase Profiling Of NCGC00685960 For The NNMT1 Project In Ncats Etb; Period Of Performance September 24, 2020 - November 5, 2020$14K
Aug 2020Federal contractHealth and Human S · Testing Of 20 Compounds Against The AKT1 And LATS1 Compounds In A Nanobret Target Engagement Intracellular Kinase Assay.$18K
May 2020Federal contractHealth and Human S · To Obtain Kinase Hotspot Assay Compound Testing Services From Reaction Biology Corporation.$29K
May 2020Federal contractHealth and Human S · Protease Profiling For 3 Ncats Etb Compounds: 3 Compounds Vs. 41 Tier 1 Proteases, 10 Dose IC50 Singlet Assay; 3 Compounds Vs. 20 Tier 2 Proteases, 10 Dose IC50 Singlet Assay; And 3 Compounds Vs. 4 Tier 3 Proteases, 10 Dose IC50 Singlet Assay.$33K
Jan 2020Federal contractHealth and Human S · This Purchase Order Is For The Testing 15 Novel Small Molecule Compounds Using The Kinase Hotspot Assay Platform.$118K
Jan 2020Federal contractHealth and Human S · Obtain IC50 Values For Compound-induced Cytotoxicity Within A 120-CELL Line Panel That Would Assist US In Determining What Cancer Has Inherent Vulnerabilities To OTS964.$15K
Jan 2020Federal contractHealth and Human S · To Obtain The Testing Of Forty-three (43) Compounds Against The AKT1 And LATS1 Compounds In A Nanobret Target Engagement Intracellular Kinase Assay.$26K
Sep 2019Federal contractHealth and Human S · Compound Testing For Inhibition Of Kinase Enzymes And Block Of Cardiac Ion Channels From Reaction Biology Corporation$109K
Aug 2019Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 Lab Testing Service 1 Cmpd Vs 100 Cancer Cell Line Panel$20K
Jul 2019Federal contractHealth and Human S · To Obtain Contractor Services For The Testing Of Compounds For Kinase Inhibition From Reaction Biology Corporation.$35K
Jun 2019Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 [19-004202]$18K
May 2019Federal contractHealth and Human S · Compound Testing Services From Reaction Biology CORPORATION:1186704 [19-003434]$150K
Mar 2019Federal contractHealth and Human S · Testing Of Compounds Versus Wild-type Kinases From Reaction Biology CORPORATION:1186704 [19-001667]$102K
Mar 2019Federal contractHealth and Human S · Igf::ot::igf$14K
Sep 2018Federal contractHealth and Human S · Reaction Biology Corporation To Provide Testing Services For Assay Screens.$23K
Sep 2018Federal contractHealth and Human S · Testing Of Compounds For Inhibition Of ROCK1, Pka And Pkca$11K
Jun 2018Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 [18-004369]$24K
May 2018Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 [18-003361] - The Purpose Of This Procurement Is For The Testing Of Compounds For Inhibition Of LATS1, LATS2 And Related Kinases$11K
May 2018Federal contractHealth and Human S · Testing Of Compounds For IRAK1, IRAK4, FLT3, And Kinase Inhibition Reaction Biology CORPORATION:1186704 [18-003496]$23K
Mar 2018Federal contractHealth and Human S · Testing Of Compounds For Inhibition Of LATS1, LATS2 And AKT1 Kinases Reaction Biology CORPORATION:1186704 [18-002261]$5K
Jan 2018Federal grantHealth and Human S · Phase II · Product Development for Bromodomain Networks$713K
Dec 2017Federal contractHealth and Human S · Reaction Biology CORPORATION:1186704 [18-000711]$7K
Sep 2017Federal contractHealth and Human S · Igf::ot::igf Reaction Biology CORPORATION:1186704 [17-005437]$14K
Sep 2017Federal contractHealth and Human S · Igf::ot::igf Reaction Biology CORPORATION:1186704 [17-006624]$24K
Sep 2017Federal contractHealth and Human S · Igf::ot::igf Reaction Biology CORPORATION:1186704 [17-006111]$10K
Jun 2017Federal contractHealth and Human S · Igf::ot::igf Other Functions - Kinase Hotspot Profiling$8K
Apr 2017Federal contractHealth and Human S · Igf::ot::igf Testing Services [17-003636]$9K
Apr 2017Federal contractHealth and Human S · Igf::ot::igf [17-002976] 57 Cmpds. Vs. 50 Kinases, 10 Dose IC50 Singlet Assay$22K
Apr 2017Federal grantHealth and Human S · Phase II · Epigenetic Probes for HMTs$765K
Mar 2017Federal contractHealth and Human S · Igf::ot::igf Reaction Biology CORPORATION:1186704 [17-002927]$6K
Jan 2017Federal grantHealth and Human S · Phase II · Product Development for Bromodomain Networks$849K
Nov 2016Federal contractHealth and Human S · Pots 17-000265 Recombinant Enzyme$4K
Aug 2016Federal contractHealth and Human S · Igf::ot::igf$54K
Aug 2016Federal contractHealth and Human S · Igf::ot::igf$17K
Apr 2016Federal contractHealth and Human S · Igf::ot::igf Kinase Profiling$25K
Apr 2016Federal contractHealth and Human S · Igf::ot::igf$121K
Apr 2016Federal grantHealth and Human S · Phase I · Probe Development for Histone Demethylase Networks$248K
Mar 2016Federal grantHealth and Human S · Phase II · Epigenetic Probes for HMTs$697K
Aug 2015Federal contractHealth and Human S · Igf::ot::igf$149K
Jul 2015Federal grantHealth and Human S · Phase I · Fluorescence Polarization Probes for Universal Coverage of the Human Bromodomains$223K
Apr 2015Federal grantHealth and Human S · Phase I · Probe Development for Bromodomains Networks$290K
Mar 2015Federal contractHealth and Human S · Igf::ot::igf Reaction Biology Corporation - Full Kinome Profile For 40 Small Molecules$75K
Dec 2014Federal contractHealth and Human S · Igf::ot::igf$4K

Federal awards are summed by year (66 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 42 peers

Line = median

Biotech · Instrument

Federal grantsBelow median
Granted patents#17 · top 40%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 2 granted of 8

Sep 29, 2026New patentKinase Inhibitors For The Treatment Of Neurodegenerative DiseasesUSPTOUS 12,747,234
Mar 5, 2026PendingKinase Inhibitors For The Treatment Of Neurodegenerative DiseasesUSPTOApplication 19321360
Oct 21, 2025GrantedKinase Inhibitors For The Treatment Of Neurodegenerative DiseasesUSPTOUS 12,448,375

Show all 8 patent records

Kinase Inhibitors For The Treatment Of Neurodegenerative DiseasesSep 29, 2026 · US 12,747,234Granted
Kinase Inhibitors For The Treatment Of Neurodegenerative DiseasesMar 5, 2026 · Application 19321360Pending
Kinase Inhibitors For The Treatment Of Neurodegenerative DiseasesOct 21, 2025 · US 12,448,375Granted
Kinase Inhibitors For The Treatment Of Neurodegenerative DiseasesJul 25, 2024 · Application 18249147Pending
Kinase Inhibitors For The Treatment Of Neurodegenerative DiseasesApplication PCTUS2021054540Pending
Thiophenyl-Pyrazolourea Derivatives as Potent, Brain Penetrant, Orally Bioavailable, and Isoform-Selective JNK3 InhibitorsApplication 63092333Pending
Kinase Inhibitors For The Treatment Of Neurodegenerative DiseasesApplication PCTUS2020050111Pending
JNK3-SELECTIVE Inhibitors For The Treatment Of Neurodegenerative DiseasesApplication 62898878Pending

Senti Biosciences Holdings, Inc.Similar federal contract value in Biotech · $2.6M in contracts
Senti Biosciences, Inc.Similar federal contract value in Biotech · $2.6M in contracts
TECHULON, INC.Similar federal contract value in Biotech · $2.5M in contracts
PROTEIOS TECHNOLOGY, INC.Similar federal contract value in Biotech · $2.5M in contracts
STEMINA BIOMARKER DISCOVERY, INCSimilar federal contract value in Biotech · $2.5M in contracts
Vetigenics LLCSimilar federal contract value in Biotech · $2.4M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.